Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ: NPCE).

The analyst commented, “We reiterate our Overweight rating and 12-month price target of $16 on NeuroPace (NPCE) following our survey of epileptologists, neurologists, and neurosurgeons. Specifically, we surveyed 30 physicians to gauge perceptions around the likelihood of FDA approval, interest in adopting RNS for idiopathic generalized epilepsy (IGE), and to better understand clinical awareness, treatment preferences, and referral patterns related to the RNS System in community practice. We came away from the survey incrementally confident in NPCE's ability to receive FDA approval and drive adoption of the RNS System in the IGE patient population, given the majority of respondents view the NAUTILUS data positively and believe NPCE will receive an expanded indication.

For an analyst ratings summary and ratings history on NeuroPace Inc click here. For more ratings news on NeuroPace Inc click here.

Shares of NeuroPace Inc closed at $11.83 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker